FGFR TYROSINE KINASE INHIBITORS AND ANTI-PD1 AGENTS FOR THE TREATMENT OF UROTHELIAL CARCINOMA

摘要

Disclosed herein are methods of treating urothelial carcinoma. In particular, the disclosed methods include combination therapies for the treatment of urothelial carcinoma comprising administering a fibroblast growth factor receptor (FGFR) inhibitor and an anti- PD1 antibody or antigen binding fragment thereof.